Asco Group Ltd.

Ym Biosciences Reports Positive Nimotuzumab Four-year Survival Data Presented At Astro 2009.(Clinical report)
Cancer Weekly; 11/17/2009; 1510 words; ...month survival data presented at ASCO 2009 and demonstrate that the...efficacy results in the control groups in this trial were similar to...trial was sponsored by Biocon Ltd., the licensee from CIMAB...trial was presented at the 2009 ASCO Annual Meeting and is entitled...

ImClone's Phase III Erbitux Trial In NSCLC Fails To Hit Endpoint.
BIOWORLD Today; 11/3/2009; 1360 words; ...Han Li, with Stanford Group Co., in a research report...Results disclosed at ASCO indicated Avastin might...Hoffmann-La Roche Ltd., of Basel, Switzerland...note at the time of the ASCO data that any decline...Li, with the Stanford Group, has "low expectations...

Positive Early Data Halting Herceptin Phase III Studies.
BIOWORLD Today; 11/3/2009; 1649 words; ...exceptional" detailed results at the ASCO meeting. Colleen Wilson, spokeswoman...North Central Cancer Treatment Group (NCCTG) conducted the trials...based Chugai Pharmaceutical Co. Ltd., and internationally by Genentech...owner F. Hoffmann-La Roche Ltd., of Basel, Switzerland...

YM BIOSCIENCES REPORTS POSITIVE NIMOTUZUMAB FOUR-YEAR SURVIVAL DATA PRESENTED AT ASTRO 2009.
PR Newswire; 11/2/2009; 1780 words; ...month survival data presented at ASCO 2009 and demonstrate that the...efficacy results in the control groups in this trial were similar to...trial was sponsored by Biocon Ltd., the licensee from CIMAB...trial was presented at the 2009 ASCO Annual Meeting and is entitled...

Ipsen and Spirogen Redesign Their Collaboration for the Development of SJG-136 (Now SG2000).
Business Wire; 10/8/2009; 1902 words; ...FR0010259150; IPN) and Spirogen Ltd. announced today that...specialised private equity group which will provide both...solid tumors cancer at ASCO 2008. About Ipsen Ipsen...specialty pharmaceutical group with over 20 products...engineering platform give the Group a competitive edge in...